Got $10,000? I’d buy these ASX 200 shares right now

If I had $10,000 to invest in S&P/ASX 200 Index (ASX: XJO) shares today, I would focus on quality rather than chasing the market’s most speculative names.

These are two ASX 200 shares I would consider buying right now.

ResMed Inc (ASX: RMD)

ResMed is an ASX 200 share I would consider buying today with part of the $10,000.

The company is a global leader in sleep apnoea treatment and connected care. Its devices help patients start therapy, while masks, accessories, software, and data tools support ongoing treatment.

What I like about ResMed is the combination of medical need and repeat use.

Sleep apnoea is not a one-off issue for many patients. Once someone is diagnosed and starts therapy, they tend to need ongoing support, replacement masks, accessories, monitoring, and software-linked care.

That can create a strong relationship between the company, clinicians, providers, and patients, as well as recurring revenue.

I also like that the market opportunity remains very large. Sleep health is still underdiagnosed in many places, and awareness should keep improving as healthcare systems focus more on chronic conditions, fatigue, cardiovascular risk, and quality of life.

ResMed is not immune to competition, pricing pressure, product cycles, or regulatory changes. Investors also need to watch how weight-loss drugs affect diagnosis and treatment behaviour over time.

But I think it has a strong global position in the healthcare market, which should remain important for decades to come.

Commonwealth Bank of Australia (ASX: CBA)

Another ASX 200 share I would buy is the Commonwealth Bank of Australia.

CBA often looks expensive compared with the other major banks. That is a fair point, and valuation always needs to be considered.

But I think CBA’s premium reflects a genuinely strong franchise.

The bank has a central role in Australian financial life. It touches mortgages, deposits, everyday transaction accounts, credit cards, business banking, merchant services, payments, and digital banking.

That gives CBA scale, data, trust, and regular customer engagement.

I think the digital side is particularly important to the investment thesis. Banking is not just about branch networks anymore. Customers expect fast apps, simple payments, useful tools, and a reliable experience. CBA has invested heavily in that area, and I think it helps strengthen the customer relationship.

Bad debts, margins, funding costs, and regulation remain risks. But I believe CBA has the management team and franchise strength to navigate these risks over time and continue growing earnings and dividends.

Foolish Takeaway

A $10,000 investment can be split across businesses that do very different things.

I would want companies with strong positions, long-term relevance, and the ability to keep adapting as conditions change. These two shares will not be perfect in every market environment, but I think they offer a useful blend of quality, growth, income potential, and resilience.

That is why I would be happy to put money into them today.

The post Got $10,000? I’d buy these ASX 200 shares right now appeared first on The Motley Fool Australia.

More reading

• Forget CBA and buy these ASX dividend shares
• What does the RBA decision mean for the big four bank shares?
• 6 ASX 200 shares with fresh buy ratings this week
• Brokers rate these 4 ASX 200 shares as a sell!
• Here’s the dividend forecast out to 2027 for CBA shares

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.